FERROSAN MEDICAL DEVICES A/S
FERROSAN MEDICAL DEVICES A/S is a Denmark-based medical devices company focused on products used to manage bleeding in surgical and other hospital procedures. The business develops, manufactures, and commercializes biomaterial-based hemostatic products and related device solutions through a multi-site operating structure.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2021–2025
Liiketoiminta
Osuus liikevaihdostaAbsorbable products used to control bleeding during surgery and procedures.
Gelatin-based and other biomaterial device platforms for surgical use.
Development of new biomaterial device products and related applications.
Asiakkaat
The company sells into hospitals and surgical care settings that need dependable bleeding-control products for operating rooms and procedural specialties. Its customer base is primarily healthcare providers and healthcare procurement organizations that buy these products for use in surgery, trauma care, and other invasive procedures. Demand is tied to clinical adoption, hospital purchasing standards, and the need for effective hemostasis in complex procedures.
Buy hemostatic products for routine and complex procedures where bleeding control is critical.
Use products in operating rooms across cardiovascular, spine, general, and other surgeries.
Select products based on clinical performance, availability, and contracting terms.
May support access to hospital customers in certain markets and channels.
Strategia
The company’s strategy centers on advancing biomaterial-based device products, including completed and in-progress development projects. It also emphasizes product pipeline development, impairment monitoring of development assets and goodwill, and maintaining operational capacity across its manufacturing footprint.
New products expand the addressable market and support long-term pipeline value.
Core products must remain clinically relevant and reliable to retain hospital use.
Development projects, trademarks, and goodwill require regular impairment assessment.
Maantiede
FERROSAN MEDICAL DEVICES operates from Denmark and reports operational control over two sites, including a site in Poland mentioned in its sustainability disclosures. The available report excerpt does not provide a full revenue-by-country split, so the profile reflects the company’s known Nordic and European operating footprint rather than an exact sales map.
Riskit
The main risks are tied to clinical adoption, regulatory certification, and the success of development projects in a specialized medical device market. The company also faces execution risk from manufacturing operations, commodity and energy inputs, and impairment risk if expected product cash flows do not materialize.
- Regulatory and certification limitsVaikutus: KorkeaTodennäköisyys: Kohtalainen
Some uses may fall outside product certifications, which can constrain market access and claims.
Kohdistuu: SPONGOSTAN certification scope
- Development project underperformanceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Capitalized development assets depend on future sales and technical success.
Kohdistuu: Biomaterial Devices pipeline
- Hospital demand and procurement pressureVaikutus: KeskitasoTodennäköisyys: Korkea
Sales depend on hospital budgets, purchasing cycles, and clinical preferences.
Kohdistuu: Surgical end markets
- Manufacturing and site disruptionVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Production is concentrated in a small number of controlled sites, increasing operational dependency.
Kohdistuu: Two operational sites
Kirjanpito
Harkinnanvaraiset erätCapitalized biomaterial projects depend on future economic benefits and can be impaired if forecasts weaken.
Vaikutus: Affects intangible assets and operating profit
Goodwill is allocated to Biomaterial Devices and tested against future cash flow assumptions.
Vaikutus: Can create large non-cash charges
Recoverable amounts rely on long-range budget assumptions and market growth estimates.
Vaikutus: Highly sensitive to discount rates and sales forecasts
Energy and waste methodology changes make reported ESG metrics less comparable year to year.
Vaikutus: Affects trend analysis rather than financial statements
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
United Health Products, Inc.
UEEC · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
Aethlon Medical, Inc
AEMD · Surgical & Medical Instruments & Apparatus
TriSalus Life Sciences, Inc.
TLSI · Surgical & Medical Instruments & Apparatus
TriSalus Life Sciences is a U.S.-based medical device company focused on catheter-based infusion systems used in interventional oncology procedures.
Asker Healthcare Group
ASKER · Health Care
Asker Healthcare Group is a prominent European provider of medical products and solutions, focusing on improving patient outcomes and reducing healthcare costs.
Cerus Corporation
CERS · Surgical & Medical Instruments & Apparatus
Cerus Corp develops and commercializes the INTERCEPT Blood System, a pathogen-reduction platform used to treat donated blood components before transfusion.
Päivitetty: 24.10.2026